In summary, by investigating the patients grouped according to their allele type of KCNQ1OT1 and methylation status of KCNQ1OT1 promoter, we concluded that the drug resistance in the treatment of colon cancer is most promoted in patients not carrying allele 10 and non-methylated in KCNQ1OT1 promoter. Here, KCNQ1OT1 is linked to malignant colon neoplasm.